Mariner LLC lifted its holdings in shares of McKesson Co. (NYSE:MCK - Free Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,579 shares of the company's stock after buying an additional 2,802 shares during the period. Mariner LLC owned approximately 0.06% of McKesson worth $43,644,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the company. Millstone Evans Group LLC purchased a new stake in McKesson during the fourth quarter valued at about $28,000. Synergy Asset Management LLC acquired a new stake in McKesson in the fourth quarter valued at $32,000. Crews Bank & Trust acquired a new position in McKesson in the fourth quarter worth about $33,000. Atala Financial Inc bought a new stake in shares of McKesson in the 4th quarter valued at approximately $34,000. Finally, Graney & King LLC acquired a new position in shares of McKesson in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 85.07% of the company's stock.
Insider Buying and Selling
In other McKesson news, EVP Leann B. Smith sold 188 shares of the business's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total transaction of $114,602.92. Following the transaction, the executive vice president now owns 1,051 shares in the company, valued at $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Brian S. Tyler sold 8,961 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the sale, the chief executive officer now directly owns 69,625 shares of the company's stock, valued at $41,820,952.50. This represents a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,110 shares of company stock worth $10,855,706. 0.11% of the stock is owned by corporate insiders.
Analyst Ratings Changes
MCK has been the subject of a number of research analyst reports. Bank of America upped their target price on McKesson from $665.00 to $755.00 and gave the stock a "buy" rating in a research report on Friday, April 11th. Cfra Research cut McKesson from a "moderate buy" rating to a "hold" rating in a research report on Friday, April 4th. Mizuho raised their price target on McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a report on Thursday, April 3rd. Wells Fargo & Company increased their price objective on shares of McKesson from $641.00 to $691.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Finally, Citigroup dropped their price target on McKesson from $713.00 to $677.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, McKesson currently has an average rating of "Moderate Buy" and an average target price of $668.50.
Get Our Latest Analysis on MCK
McKesson Trading Down 1.2 %
Shares of MCK stock traded down $8.38 during trading hours on Monday, hitting $688.70. 154,643 shares of the company's stock were exchanged, compared to its average volume of 921,805. The company has a market capitalization of $86.31 billion, a PE ratio of 31.53, a PEG ratio of 1.29 and a beta of 0.49. The business's 50 day simple moving average is $651.89 and its 200-day simple moving average is $601.00. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $728.32.
McKesson (NYSE:MCK - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Equities analysts anticipate that McKesson Co. will post 32.77 EPS for the current year.
McKesson Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Monday, March 3rd were given a $0.71 dividend. The ex-dividend date of this dividend was Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.41%. McKesson's dividend payout ratio (DPR) is presently 13.00%.
About McKesson
(
Free Report)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Further Reading
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
